Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms

BACKGROUND: Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on atherogenesis and the relevant mechanisms. METHODS: For in vitro studies, primary cu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Tian, Yuling, Chen, Tao, Wu, Yan, Yang, Lin, Wang, Lijun, Fan, Xiaojuan, Zhang, Wei, Feng, Jiahao, Yu, Hang, Yang, Yanjie, Zhou, Juan, Yuan, Zuyi, Wu, Yue
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663071/
https://ncbi.nlm.nih.gov/pubmed/29084546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0623-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky